Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New automated bone marker assay launched:

This article was originally published in Clinica

Executive Summary

Ortho-Clinical Diagnostics has introduced its Vitros automated bone marker assay designed to measure levels cross-linked N-telopeptides (NTx) associated with bone resorptive diseases such as osteoporosis. Results from the test, which is the first automated system for NTx, takes approximately 37 minutes - increased levels of NTx indicate an increase in bone resorption. The assay is designed to be used in conjunction with bone density imaging for monitoring bone health.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT077793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel